Centene (CNC) Q1 2026 earnings review
A Turnaround Quarter: Profitability Restored as Centene Shrinks to Grow Stronger
Centene delivered a massive Q1 beat, proving its aggressive turnaround plan is working. After a disastrous mid-2025 where unexpected medical costs crushed earnings, management made the painful choice to prioritize margins over volume. They repriced their Marketplace business—shedding over 2 million members—and fought for higher Medicaid rates. The result? Adjusted EPS hit $3.37, beating internal expectations by $0.50. The critical Medicaid Health Benefits Ratio (HBR) cooled to 93.1%, down from the crisis peak of 94.9% in 25Q2. With Q1 securing the bulk of the year's profit, management confidently raised the FY26 EPS floor to >$3.40.
🐂 Bull Case
The Medicaid HBR improved to 93.1% (down 50 bps YoY), proving that rate increases and targeted medical cost management are effectively offsetting earlier trend spikes in behavioral and home health.
By intentionally shrinking the Marketplace book by ~36% to avoid unprofitable, high-acuity members, Centene stabilized the segment's pre-tax earnings.
🐻 Bear Case
Total at-risk membership dropped by 1.67 million YoY. While the Marketplace cuts were intentional, Medicaid also lost over 500,000 members, limiting the long-term premium growth runway.
The $4.36B operating cash flow figure looks spectacular but was heavily inflated by a $1.0B off-balance-sheet sale of CMS receivables.
⚖️ Verdict: 🟢
Bullish. Health insurers make the vast majority of their money in Q1. Securing $3.37 in adjusted EPS right out of the gate dramatically de-risks the rest of the year and confirms the 2025 morbidity crisis is largely contained.
Key Themes
Medicaid Margin Recovery
Accelerating. The most critical metric for Centene is the Medicaid Health Benefits Ratio (the percentage of premiums spent on medical care). After blowing up to 94.9% in 25Q2, management forced rate increases and cracked down on provider fraud. The ratio has now sequentially improved for three straight quarters, landing at a healthy 93.1% in Q1.
Shrinking the Marketplace to Save the Bottom Line
Reversing. In 2025, an influx of high-acuity (sicker) members into the Marketplace triggered a massive $2.4 billion earnings shortfall. Centene's response was brutal but effective: they aggressively raised prices. As a result, Marketplace membership plummeted from a peak of 5.86 million in 25Q2 to 3.58 million today. Despite the revenue hit, segment pre-tax earnings are now tracking in line with expectations.
AI-Driven Payment Integrity
Stable. A key lever in controlling the runaway medical costs of 2025 has been the deployment of GenAI and algorithmic scoring. Management noted in recent quarters that claims are now scored against 75 algorithms to detect potential fraud and abuse, directly contributing to the lower Q1 SG&A ratio (7.6%) and improved HBR.
Silver Tier Acuity Contradicts the 'Clean' Narrative
Despite the massive price hikes designed to purge unprofitable members, the Commercial HBR came in at 75.3%—slightly above management's expectations. The culprit is higher acuity among Silver Tier members. While Centene expects a net risk adjustment benefit later in the year to offset this, the raw data shows the risk pool still runs slightly hotter than modeled.
Cash Flow Inflated by Factoring Receivables
Operating Cash Flow surged to $4.36B (up from $1.51B a year ago). However, this number is structurally inflated. Centene sold a $1.0B participating interest in its 2025 CMS Part D risk-sharing receivables to get cash upfront, absorbing a $30M loss on the sale. Without this financial engineering, cash flow growth would be far less pronounced.
Macro Pressures: The D-SNP Transition
A major regulatory shift occurred this quarter: the CMS transition to Dual Eligible Special Needs Plans (D-SNP) based integration. This moved roughly 85,000 members out of Medicaid and into the Medicare segment. Managing the care and compliance for these highly complex, dual-eligible populations under new CMS frameworks poses ongoing operational risk.
Other KPIs
Decelerating. Growth slowed to 5% YoY, down from the 17-21% growth rates seen in 2025. The slowdown is entirely intentional, driven by the purposeful exit of over 2 million unprofitable Marketplace members. Medicare PDP revenues provided the primary upside.
Accelerating efficiency. Down from 7.9% a year ago. The company effectively leveraged expenses over higher PDP revenue while shedding the Marketplace members that traditionally require much higher administrative and customer service overhead.
Centene utilized the $970M in cash proceeds from its CMS receivable sale to directly repurchase $1.0B of its senior notes due 2027. This brings total debt down to $16.4B and eliminates near-term interest rate exposure, leaving the $4.0B revolving credit facility completely undrawn.
Guidance
Accelerating. Raised from the previous floor. With $3.37 already in the bank from Q1, this guidance might look absurdly low to a layperson. However, health insurers structurally realize the vast majority of their earnings in Q1 before deductibles are met, and typically post losses in Q4. Securing $3.37 now makes the >$3.40 full-year target highly achievable.
Raised by $1.0 billion from prior expectations, driven primarily by strength in the Medicaid segment's state-directed payments and rate increases.
Key Questions
Silver Tier Morbidity
The Commercial HBR of 75.3% missed internal targets due to Silver Tier acuity. How much of an offset are you explicitly modeling for the 2026 net risk adjustment, and what happens if that CMS transfer falls short of your estimates like it did in 2025?
Sustainability of Factoring Receivables
You took a $30M loss to pull forward $970M in cash by selling 2025 CMS receivables. Is this an ongoing capital strategy we should model for future quarters, or a one-time maneuver to quickly retire the 2027 senior notes?
Medicaid Member Attrition
Traditional Medicaid membership is down roughly 440,000 members year-over-year. Are we nearing the absolute floor of post-pandemic redetermination attrition, or should we expect continued steady bleeding through the rest of 2026?